RLYB Rallybio Corporation
USHealthcareAs of 2026-07-10 16:00
Why RLYB matters now
Rallybio Corporation (RLYB) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.73 with -0.63% on the session and $91.2M in market capitalization; recent performance reads 1-month +12.54% and YTD +190.89%.
The latest financial table shown here is Q1 2026, with revenue of $212.0K, net income of $-8.3M, and EPS of $-1.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -29.8%.
The latest indexable market news headline is "Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?" from GuruFocus.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes ADAR1 Capital Management, LLC filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.81
P/S
107.96
EV/EBITDA
-1.83
DCF Value
$10.91
FCF Yield
-29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-3278.2%
Net Margin
-911.1%
ROE
-14.4%
ROA
-14.4%
ROIC
-55.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $212.0K | $-8.3M | $-1.46 |
| Q4 2025 | $222.0K | $-5.9M | $-1.11 |
| FY 2025 | $858.0K | $-9.0M | $-1.59 |
| Q3 2025 | $212.0K | $16.0M | $2.84 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.88
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.